Locations:
SearchAdvertisement
Learn about featured clinical trials currently enrolling or search our trials database
Cell study upends thinking about VEGF-A
Combination therapy shows improved response in some
SGN-CD33A demonstrates encouraging antileukemic activity
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A new discovery may help slow the growth of tumors — and change the research and treatment of cancer.
Learn about featured clinical trials currently enrolling or search our trials database
Surprisingly, no, study finds
Technique translated from colorectal cancer successes
An overarching goal of healthcare delivery is to improve the value of care defined as patient outcomes per dollar spent. With that in mind, a recent Cleveland Clinic study of two chemoradiation (ChemoRT) regimens for stage III-IV squamous cell carcinoma of head and neck (HNSCC) compared the outcomes and costs of the protocols.
Advertisement
Advertisement
